A world first in imaging technology

Monash College has launched the world’s first technology that can detect magnetic nanoparticles anywhere in the body, enabling advanced medical functions similar to the monitoring of CAR-T cells useful during most cancer treatments.

The brand new expertise was funded through an ARC LIEF grant with contributions from Monash College and RMIT, and combines magnetic particle imaging (MPI) with computed tomography (CT) and hyperthermia capabilities for preclinical in vivo analysis . It is located on the Monash Alfred campus and is operated by the Alfred Analysis Alliance-Monash Biomedical Imaging (ARA-MBI) platform.

MPI is a brand new, non-invasive molecular imaging approach that delivers significantly enhanced tracer sensitivity over MRI and remarkably faster acquisition opportunities compared to nuclear medicine, for interdisciplinary tasks in medical analysis, chemistry and biotechnology. Opens doors to innovative options.

The Preclinical Momentum MPI System, developed by Magnetic Perception, is the world’s first MPI system with CT and hyperthermia capabilities.

The expertise quantitatively detects magnetic nanoparticles anywhere within the body with specific sensitivity, allowing researchers to detect nanoparticles in vivo, where they will bind to specific cells of interest. Using similar in vivo living subject, hyperthermia expertise can then profile a spot with pin-point accuracy and induce local heating at this location, high enough to kill cells to the desired therapeutic temperature. Designed to be ensured with nanoparticles.

The capabilities could also monitor chemotherapy treatments and improve their efficacy with the addition of concentrated heating. “With most cancer tissue currently reaching only 0.01 pc of chemotherapy, it is very important to spice up the efficiency of the drug to reach the target,” said Dr Karen Alt, head of the NanoTheranostics Laboratory at the Australian Center for Blood Illness. Monash College.

“MPI and focused hyperthermia are seen as perhaps the most promising new developments within the non-invasive diagnostic imaging and treatment field in many years because it combines the non-invasive nature of MRI with the sensitivity of PET, allowing two to three The best are integrated into mainstream medical modalities,” said Associate Professor Christoph Heijmeyer, head of the Nano Biotechnology Laboratory at the Australian Center for Blood Illness, Monash College.

The ARA-MBI platform gives preclinical researchers access to the latest imaging tools integrating highly decision-making imaging and diagnostics to tailor personalized therapeutic targets. Applied sciences include magnetic resonance imaging (MRI), MPI and positron emission tomography (PET)/CT scanners.

Monash and its partners are world-leaders in improved nanoparticle fabrication, which is critical to reaching the full potential of MPI. This is because MPI judgment and sensitivity are pushed as much by the properties of the magnetic tracer as the imaging {hardware}.

The capability will be used to develop specialized iron oxide nanoparticles with the best MPI sensitivity and response, enabling new options for analysis in critical analysis areas, equivalent to vaccine expertise development.

Dr Patrick Goodwill, skilled in Magnetic Particle Imaging (MPI) expertise and Co-Founder and CEO of Magnetic Perception, said: “We are now working with TrendBio (an Australian SME) to ship and support this unprecedented expertise. And we’re excited to see the results the Monash researchers send in.”

Professor Mike Ryan, Educational Director, Analysis Infrastructure, Monash College, said: “The capability will further improve the management of Monash in the better supply science nanotechnology, molecular imaging and biosciences.”

This content comes from the original group and may also be of a periodic nature, edited for readability, fashion and size.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *